Welcome to the WSPID 2022 Virtual Congress Calendar
All sessions in the calendar are in Eastern Standard Time (GMT-5/UTC-5) – Cancun time. To convert the conference time
to your local time - Click Here
The viewing of sessions and E-Posters cannot be accessed from this conference calendar.
All content is accessible only via the WSPID Virtual Platform.
Pre-Congress days – 20-21 February
Main Congress days – 22-24 February
- Fully Live Session - Semi-live session with Live Q&A - Voting - On Demand Session (watch anytime)
OVERVIEW OF TAKEDA’S TETRAVALENT DENGUE VACCINE CANDIDATE CLINICAL DEVELOPMENT TO DATE
Dengue is a mosquito-borne viral disease endemic in at least 128 countries and a potential threat for travelers to these countries.
Takeda’s vaccine candidate (TAK-003) is a recombinant tetravalent dengue vaccine based on a DENV-2 backbone. The clinical development program includes an ongoing long-term Phase III efficacy clinical trial in eight dengue endemic countries evaluating long-term efficacy, safety, and immunogenicity which currently has 3 years data available.
Overall, 18 clinical trials have included 28,175 participants aged 1.5-60 years in 13 endemic and non-endemic countries. In the Phase III efficacy study, healthy 4–16 year-olds (n=20,099) were randomized 2:1 to receive two doses of TAK-003 or placebo three months apart, and are under active febrile illness surveillance to detect symptomatic dengue.
Safety and immunogenicity data from Phase I/II studies established the final formulation and dosing schedule. In the pivotal Phase III efficacy study the cumulative vaccine efficacy from first dose through three years after the second dose was 62.0% (95% Confidence Interval: 56.6–66.7) against virologically confirmed dengue (VCD) and 83.6% (76.8–88.4) against hospitalized VCD for safety set. Efficacy varied by serotype and some decline in efficacy was noted in a year-to-year comparison but remained robust against hospitalized VCD. Rates of serious adverse events were similar between the vaccine and placebo groups. No important safety risk was identified.
TAK-003 was well tolerated and protected against symptomatic dengue over three years after vaccination in both dengue-naïve and pre-exposed children in dengue endemic countries with no evidence of disease enhancement to date.
CODOMINANT IGG AND IGA EXPRESSION WITH MINIMAL VACCINE MRNA IN MILK OF BNT162B2 VACCINEES
Lactating women can produce protective antibodies in their milk after vaccination, which has informed antenatal vaccination programs for diseases such as influenza and pertussis. However, whether SARS-CoV-2-specific antibodies are produced in human milk as a result of COVID-19 vaccination is still unclear.
Our aims are (1) to longitudinally quantify SARS-CoV-2-specific IgA and IgG in human milk of lactating women who received COVID-19 mRNA vaccine, with reference to a cohort convalescent from antenatal COVID-19 as well as a control cohort of healthy lactating women, and (2) to detect and quantify vaccine mRNA in human milk after vaccination.
Prospective cohort study of a convenience sample of lactating healthcare workers living in Singapore, who were due to receive two doses of the BNT162b2 (Pfizer/BioNtech) vaccine/ We collected milk samples at 5 time points.
Lactating mothers who received the BNT162b2 vaccine secreted SARS-CoV-2-specific IgA and IgG antibodies into milk, with the most significant increase at 3–7 days post-dose 2. Virus-specific IgG titers were stable out to 4–6 weeks after dose 2. In contrast, SARS-CoV-2-specific IgA levels showed substantial decay. Vaccine mRNA was detected in few milk samples (maximum of 2 ng/ml), indicative of minimal transfer. Infants who consumed post-vaccination human milk had no reported adverse effects up to 28 days post-ingestion.
Our results define the safety and efficacy profiles of the vaccine in this demographic and provide initial evidence for protective immunity conferred by milk-borne SARS-CoV-2-specific antibodies. Taken together, our study supports recommendations for uninterrupted breastfeeding subsequent to mRNA vaccination against COVID-19.
ANALYSIS OF CERVICAL ABNORMALITIES IN A BRAZILIAN CITY AFTER IMPLEMENTATION OF QUADRIVALENT VACCINE AGAINST HPV IN GIRLS 10 TO 15 YEARS IN 2010
Human papillomavirus (HPV) is the most common viral infection of the reproductive tract,which is why it is considered a public health problem.Campos dos Goytacazes is the first city in Brazil who introduced in 2010 the quadrivalent HPV vaccine (4vHPV) for girls 10-15 years old,4 years before public vaccination program
The ecological analysis evaluated the impact of HPV vaccination as a protective factor against HPV abnormalities
Results of the Pap smear test obtained from the Brazilian Ministry of Health’s SISCOLO System were categorized in low-grade abnormalities (LGA) and high-grade abnormalities (HGA).We analyzed results in pap tests before and 09 years after the vaccine introduction
In 2009 we obtained a total of 207 LGA and 63 HGA; 2010, 143 LGA and 96 HGA anomalies; 2011, 155 LGA and 115 HGA; 2012, 152 LGA and 62 HGA; 2013, 138 LGA and 46 HGA; 2014, 86 LGA and 39 HGA; 2016, 219 LGA and 87 HGA; 2017, 313 LGA and 207 HGA; 2018, 344 LGA and 205 HGA; 2019, 599 LGA and 247 HGA
After implementation of 4vHPV there was a reduction in LGA e HGA.Then, in 2016, we observed an increase in the absolute number of LGA e HGA and abrupt increase in 2019,which can be correlated with the reduction in vaccination coverage caused by reduction in government advertising and incentives for vaccination,including school vaccination strategies.Other important factors are a possible replacement of the viral type or increasing sensibility in surveillance system.Other studies most be carried out to analyze this tendency